Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784674 | 0.94 | PLAU (0.48) | STSL3MBTL1MAPTPPARGPPARA | |
| SCHEMBL6780164 | 0.87 | NPC1 (0.56) | MAPTNPC1RAB9AKMT2A | |
| SCHEMBL6690529 | 0.87 | CYP19A1 (0.48) | STSL3MBTL1PPARGPPARANPC1 | |
| SCHEMBL6777630 | 0.86 | NPC1 (0.45) | L3MBTL1NPC1RAB9AKMT2A | |
| SCHEMBL6690214 | 0.85 | POLB (0.49) | TSHR | |
| SCHEMBL2937613 | 0.85 | NPC1 (0.42) | STSL3MBTL1MAPTPPARGPPARA | |
| SCHEMBL2938988 | 0.82 | NPC1 (0.42) | STSL3MBTL1MAPTPPARGPPARA | |
| SCHEMBL23036220 | 0.80 | ALDH1A1 (0.59) | L3MBTL1MAPTNPC1RAB9ATSHR | |
| SCHEMBL2931737 | 0.80 | NPC1 (0.41) | PPARGPPARANPC1RAB9A | |
| SCHEMBL17070018 | 0.80 | ELANE (0.58) | STSSRD5A2NPC1RAB9AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-6750213-B2 | BONE DISORDERS; UROGENITAL SYSTEM DISORDERS; ANTICANCER AGENTS | MERCK & CO., INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030225132-A1 | Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders | DININNO FRANK P (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003086388-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087073-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20020165226-A1 | Estrogen receptor modulators | MERCK & CO., INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | STS 40/4885L3MBTL1 1803/4885MAPT 4652/4885 |
| US-20020165226-A1 | Estrogen receptor modulators | ESRRA, GPER1, ESRRB | STS 2761/4885L3MBTL1 2017/4885MAPT 843/4885 |
| US-20030225132-A1 | Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders | GPER1, ESR2, ESR1 | STS 991/4885L3MBTL1 2140/4885MAPT 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.